Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells

Cancer Letters

Volumn 357, Issue 2, 2015, Pages 520-526

  Yang, Lina ^a,b,c   Zhou, Yunjiao ^a   Li, Yinghua ^a   Zhou, Juan ^a   Wu, Yougen ^a   Cui, Yunqing ^a   Yang, Gong ^a,b,c   Hong, Yang ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Chemoresistance; KRAS; Lung cancer; NF B; P53

Indexed keywords

6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; CISPLATIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; K RAS PROTEIN; MUTANT PROTEIN; PACLITAXEL; PROTEIN P53; TRANSCRIPTION FACTOR RELA; ANTINEOPLASTIC AGENT; FUSED HETEROCYCLIC RINGS; I KAPPA B KINASE; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PYRIDINE DERIVATIVE; RAS PROTEIN;

A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL NUCLEUS; GENE SILENCING; H1299 CELL LINE; H358 CELL LINE; HUMAN; HUMAN CELL; LUNG CANCER; LUNG CANCER CELL LINE; MOUSE; MUTATION; NONHUMAN; PROTEIN DEFICIENCY; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; WILD TYPE; ACTIVE TRANSPORT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL CYCLE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; LUNG NEOPLASMS; METABOLISM; PROCEDURES; TUMOR CELL LINE; TUMOR VOLUME; WESTERN BLOTTING;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOGENESIS; CELL CYCLE; CELL LINE, TUMOR; CELL NUCLEUS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; I-KAPPA B KINASE; LUNG NEOPLASMS; MICE, INBRED BALB C; MUTATION; NF-KAPPA B; PACLITAXEL; PROTO-ONCOGENE PROTEINS; PYRIDINES; RAS PROTEINS; TRANSCRIPTION FACTOR RELA; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920765176     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.12.003     Document Type: Article

References (33)

1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin 2014, 64:9-29.
2. Macerelli M., Caramella C., Faivre L., Besse B., Planchard D., Polo V., et al. Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?. Lung Cancer 2014, 83:383-388.
3. Hayden M.S., Ghosh S. Signaling to NF-kappaB. Genes Dev 2004, 18:2195-2224.
4. Wang C.Y., Cusack J.C., Liu R., Baldwin A.S. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat. Med 1999, 5:412-417.
5. Garassino M.C., Marabese M., Rusconi P., Rulli E., Martelli O., Farina G., et al. Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Ann. Oncol 2011, 22:235-237.
6. Janakiraman M., Vakiani E., Zeng Z., Pratilas C.A., Taylor B.S., Chitale D., et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010, 70:5901-5911.
7. Basseres D.S., Ebbs A., Levantini E., Baldwin A.S. Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis. Cancer Res 2010, 70:3537-3546.
8. Meylan E., Dooley A.L., Feldser D.M., Shen L., Turk E., Ouyang C., et al. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 2009, 462:104-107.
9. Mogi A., Kuwano H. TP53 mutations in nonsmall cell lung cancer. J. Biomed. Biotechnol 2011, 2011:583929.
10. Guntur V.P., Waldrep J.C., Guo J.J., Selting K., Dhand R. Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro. Anticancer Res 2010, 30:3557-3564.
11. Okudela K., Yazawa T., Ishii J., Woo T., Mitsui H., Bunai T., et al. Down-regulation of FXYD3 expression in human lung cancers: its mechanism and potential role in carcinogenesis. Am. J. Pathol 2009, 175:2646-2656.
12. Ostrem J.M., Peters U., Sos M.L., Wells J.A., Shokat K.M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013, 503:548-551.
13. Stegehuis J.H., de Wilt L.H., de Vries E.G., Groen H.J., de Jong S., Kruyt F.A. TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives. Drug Resist. Updat 2010, 13:2-15.
14. Munshi A., Kurland J.F., Nishikawa T., Chiao P.J., Andreeff M., Meyn R.E. Inhibition of constitutively activated nuclear factor-kappaB radiosensitizes human melanoma cells. Mol. Cancer Ther 2004, 3:985-992.
15. Yang G., Xiao X., Rosen D.G., Cheng X., Wu X., Chang B., et al. The biphasic role of NF-kappaB in progression and chemoresistance of ovarian cancer. Clin. Cancer Res 2011, 17:2181-2194.
16. Willis A., Jung E.J., Wakefield T., Chen X. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 2004, 23:2330-2338.
17. Liu J., Yang G., Thompson-Lanza J.A., Glassman A., Hayes K., Patterson A., et al. A genetically defined model for human ovarian cancer. Cancer Res 2004, 64:1655-1663.
18. Yang G., Rosen D.G., Mercado-Uribe I., Colacino J.A., Mills G.B., Bast R.C., et al. Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. Carcinogenesis 2007, 28:174-182.
19. Barbie D.A., Tamayo P., Boehm J.S., Kim S.Y., Moody S.E., Dunn I.F., et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009, 462:108-112.
20. Liu G., Yang G., Chang B., Mercado-Uribe I., Huang M., Zheng J., et al. Stanniocalcin 1 and ovarian tumorigenesis. J. Natl. Cancer Inst 2010, 102:812-827.
21. Yang G., Rosen D.G., Zhang Z., Bast R.C., Mills G.B., Colacino J.A., et al. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:16472-16477.
22. Yang G., Rosen D.G., Liu G., Yang F., Guo X., Xiao X., et al. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin. Cancer Res 2010, 16:3875-3886.
23. Raskatov J.A., Meier J.L., Puckett J.W., Yang F., Ramakrishnan P., Dervan P.B. Modulation of NF-kappaB-dependent gene transcription using programmable DNA minor groove binders. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:1023-1028.
24. Araki K., Kawauchi K., Tanaka N. IKK/NF-kappaB signaling pathway inhibits cell-cycle progression by a novel Rb-independent suppression system for E2F transcription factors. Oncogene 2008, 27:5696-5705.
25. Setia S., Sanyal S.N. Downregulation of NF-kappaB and PCNA in the regulatory pathways of apoptosis by cyclooxygenase-2 inhibitors in experimental lung cancer. Mol. Cell. Biochem 2012, 369:75-86.
26. Godwin P., Baird A.M., Heavey S., Barr M.P., Byrne K.J.O., Gately K. Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front. Oncol 2013, 3:120.
27. Jones D.R., Broad R.M., Madrid L.V., Baldwin A.S., Mayo M.W. Inhibition of NF-kappaB sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis. Ann. Thorac. Surg 2000, 70:930-936. discussion 936-937.
28. Tang X., Liu D., Shishodia S., Ozburn N., Behrens C., Lee J.J., et al. Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer 2006, 107:2637-2646.
29. Chen W., Li Z., Bai L., Lin Y. NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target. Front. Biosci. (Landmark Ed) 2011, 16:1172-1185.
30. Gregorc V., Ludovini V., Pistola L., Darwish S., Floriani I., Bellezza G., et al. Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 2003, 39:41-48.
31. Tsao M.S., Aviel-Ronen S., Ding K., Lau D., Liu N., Sakurada A., et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J. Clin. Oncol 2007, 25:5240-5247.
32. Korobowicz E., Zdunek M. Immunohistochemical study of p53 in non-small cell lung cancer before and after preoperative chemotherapy. Pol. J. Pathol 2000, 51:71-76.
33. Campos-Parra A.D., Zuloaga C., Manriquez M.E., Aviles A., Borbolla-Escoboza J., Cardona A., et al. KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making. Am. J. Clin. Oncol 2013.